A Bout of High-Intensity Interval Training (HIIT) in Children and Adolescents during Acute Cancer Treatment-A Pilot Feasibility Study.

adrenaline childhood cancer exercise intervention feasibility heart rate high-intensity interval training lactate safety

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
12 Mar 2022
Historique:
received: 02 02 2022
revised: 28 02 2022
accepted: 10 03 2022
entrez: 25 3 2022
pubmed: 26 3 2022
medline: 26 3 2022
Statut: epublish

Résumé

Low- and moderate-intensity exercise is safe and feasible during childhood cancer treatment. The feasibility of a bout of high-intensity interval training (HIIT) in this population has not been analyzed to date. Pediatric cancer patients aged between 6 and 18 years were selected based on clinical conditions to perform ten sets of 15 s HIIT (>90% of estimated maximal heart rate (HRmax)) and 1 min active recovery on a bicycle ergometer within the first three chemotherapy courses. We assessed safety and feasibility criteria and the following parameters: perceived exertion rate, heart rate, and lactate and adrenaline concentrations. Out of 212 eligible patients, 11 patients aged 13.9 ± 3.6 years (n = 7 ♂) with lymphoma, leukemia, rhabdomyosarcoma, nephroblastoma, and synovial sarcoma completed the bout of HIIT without serious adverse events. During exercise, patients reached a BORG value maxima of 16 ± 1.2, and their heart rates rose from 78 ± 17 beats per minute (bpm) at rest to 178 ± 12 bpm after exercise (90 ± 6% estimated HRmax). The power-to-weight ratio was 2 ± 0.5 W/kg (watt per kilogram). Blood lactate concentrations increased from 1.09 ± 0.50 mmol/L (millimole per liter) at rest to 5.05 ± 1.88 mmol/L post-exercise. Our preliminary data suggest that HIIT is applicable only in a small number of childhood cancer patients. Individually adapted exercise protocols for patients with multiple impairments are needed.

Identifiants

pubmed: 35326619
pii: cancers14061468
doi: 10.3390/cancers14061468
pmc: PMC8945900
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

J Sports Sci Med. 2012 Sep 01;11(3):387-92
pubmed: 24149344
Pediatr Blood Cancer. 2017 Nov;64(11):
pubmed: 28423225
Cell. 2012 Aug 17;150(4):780-91
pubmed: 22863277
BMC Med Res Methodol. 2010 Jan 06;10:1
pubmed: 20053272
J Pediatr. 2005 Jun;146(6):732-7
pubmed: 15973308
PLoS One. 2015 Aug 28;10(8):e0136489
pubmed: 26317981
Clin J Sport Med. 2017 Mar;27(2):139-144
pubmed: 27177205
Nat Commun. 2021 Sep 30;12(1):5725
pubmed: 34593796
JAMA. 2005 May 25;293(20):2479-86
pubmed: 15914748
J Clin Oncol. 2011 Feb 20;29(6):726-32
pubmed: 21205749
Compr Physiol. 2018 Dec 13;9(1):165-205
pubmed: 30549018
Trends Cancer. 2022 Feb;8(2):110-122
pubmed: 34776398
Cell Metab. 2016 Mar 8;23(3):554-62
pubmed: 26895752
Res Q Exerc Sport. 2010 Dec;81(4):466-71
pubmed: 21268470
Front Oncol. 2020 Feb 21;10:196
pubmed: 32154183
iScience. 2020 Apr 24;23(4):100978
pubmed: 32240949
Cancer Treat Rev. 2017 Jan;52:91-104
pubmed: 28006694
Sports Med. 2017 Nov;47(11):2363-2374
pubmed: 28643209
J Clin Oncol. 2006 Aug 1;24(22):3527-34
pubmed: 16822844
Metabolism. 2015 Mar;64(3):391-5
pubmed: 25524794
Lancet Child Adolesc Health. 2018 May;2(5):321-337
pubmed: 29732397
Front Pediatr. 2021 Aug 19;9:682496
pubmed: 34490156
Cochrane Database Syst Rev. 2016 Mar 31;3:CD008796
pubmed: 27030386
Cancer Treat Rev. 2018 Nov;70:154-167
pubmed: 30218787
Pediatr Res. 2013 Oct;74(4):366-74
pubmed: 23857296
JAMA Intern Med. 2016 Jun 1;176(6):816-25
pubmed: 27183032
Trends Cancer. 2017 Jun;3(6):423-441
pubmed: 28718417
Pediatr Blood Cancer. 2016 Jan;63(1):127-32
pubmed: 26184456
Clin Transl Oncol. 2021 Jan;23(1):22-34
pubmed: 32447643
Pediatr Blood Cancer. 2018 Feb;65(2):
pubmed: 29049845
Med Sci Sports Exerc. 2019 Nov;51(11):2391-2402
pubmed: 31626056
J Am Coll Cardiol. 2001 Jan;37(1):153-6
pubmed: 11153730
J Physiol. 2012 Mar 1;590(5):1077-84
pubmed: 22289907
Support Care Cancer. 2021 Aug;29(8):4859-4866
pubmed: 33544247
Front Pediatr. 2020 Jun 05;8:243
pubmed: 32582585
Int J Behav Nutr Phys Act. 2013 Aug 15;10:98
pubmed: 23945179
Cancers (Basel). 2021 Jan 02;13(1):
pubmed: 33401713

Auteurs

Sabine Kesting (S)

Kinderklinik München Schwabing, Department of Pediatrics and Children's Cancer Research Center, TUM School of Medicine, Technical University of Munich, 80804 Munich, Germany.
Chair of Preventive Pediatrics, Department of Sport and Health Sciences, Technical University of Munich, 80992 Munich, Germany.
Pediatric Oncology Network Bavaria, KIONET Bavaria, 91054 Erlangen, Germany.

Peter Weeber (P)

Kinderklinik München Schwabing, Department of Pediatrics and Children's Cancer Research Center, TUM School of Medicine, Technical University of Munich, 80804 Munich, Germany.
Exercise Biology, Department of Sport and Health Sciences, Technical University of Munich, 80809 Munich, Germany.

Martin Schönfelder (M)

Exercise Biology, Department of Sport and Health Sciences, Technical University of Munich, 80809 Munich, Germany.

Anja Pfluger (A)

Exercise Biology, Department of Sport and Health Sciences, Technical University of Munich, 80809 Munich, Germany.

Henning Wackerhage (H)

Pediatric Oncology Network Bavaria, KIONET Bavaria, 91054 Erlangen, Germany.

Irene von Luettichau (I)

Kinderklinik München Schwabing, Department of Pediatrics and Children's Cancer Research Center, TUM School of Medicine, Technical University of Munich, 80804 Munich, Germany.
Pediatric Oncology Network Bavaria, KIONET Bavaria, 91054 Erlangen, Germany.

Classifications MeSH